The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously ...

Ad hoc-Mitteilungen: Nachrichten»Sanofi: FDA to review MenQuadfi, a meningococcal vaccine candidate Push Mitteilungen GlobeNewswire (Europe) 27.06.2019 07:05 Uhr 211 Leser Artikel bewerten: (0) ...

Sanofi SNY announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against ...

The Food and Drug Administration (FDA) has approved MenQuadfi TM Meningococcal (Groups A, C, Y, W; Sanofi Pasteur) Conjugate Vaccine for the prevention of invasive meningococcal disease caused by ...

(RTTNews) - Sanofi said that the U.S. Food and Drug Administration has approved a Biologics License Application for MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive ...

US regulators have issued a green light for Sanofi’s meningococcal vaccine MenQuadfi for the prevention of invasive meningococcal disease in persons two years of age and older. “Meningococcal ...

MenQuadfi builds on Sanofi’s legacy at the forefront of meningococcal disease prevention beginning with the first monovalent vaccine for Africa in 1974.

About MenQuadfi MenQuadfi benefits from Sanofi's latest advancements in chemical design and delivers optimized stability while maintaining the vaccine in a convenient, fully liquid presentation.

Sanofi SNY announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against ...

Sanofi is conducting additional Phase III trials in these same regions and Africa. MenQuadfi's safety and efficacy data have not yet been evaluated by any regulatory authority.